Swiss National Bank Boosts Stake in Haemonetics Co. (NYSE:HAE)

Swiss National Bank lifted its holdings in Haemonetics Co. (NYSE:HAE) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,700 shares of the medical instruments supplier’s stock after buying an additional 1,200 shares during the quarter. Swiss National Bank’s holdings in Haemonetics were worth $7,863,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of HAE. Parkside Financial Bank & Trust boosted its position in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares in the last quarter. AlphaQuest LLC boosted its position in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,826 shares in the last quarter. KBC Group NV boosted its position in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 712 shares in the last quarter. iSAM Funds UK Ltd purchased a new stake in Haemonetics during the third quarter worth $204,000. Finally, HighTower Advisors LLC boosted its position in Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 244 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research analyst reports. Raymond James reiterated a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Needham & Company LLC reduced their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Stock Performance

Haemonetics stock opened at $64.08 on Friday. The firm has a market capitalization of $3.22 billion, a P/E ratio of 25.23, a PEG ratio of 1.11 and a beta of 0.43. The stock has a fifty day moving average price of $67.29 and a 200 day moving average price of $75.03. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.